Epinex Diagnostics, Inc. could raise up to $1.7 million in private equity offering
In an SEC filing, Epinex Diagnostics, Inc. disclosed it has raised $318,000 from outside investors, and could raise up to $1.7 million in a private equity offering. Epinex is developing two handheld devices to test glycated albumin, one for us in the home and one for the doctor's office. If successful, Epinex could provide on-the-spot testing for glycated albumin, a test that's currently done through a laboratory.
Testing glycated albumin levels allows physicians and patients the ability to monitor intermediate glucose control that takes place between daily monitoring and regular A1c tests. Epinex's test, the G1A Test, "...shows how well the patients have controlled their level of glycation over the previous month."